Account
Insider Insights
09.02.2023
New criteria for ATMPs which must follow quality r...

The Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...

Read more
News
02.02.2023
PMA Insights: Week 5

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
02.02.2023
NICE has recommended Yescarta as the first CAR T-c...

NICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...

Read more
Insider Insights
25.01.2023
AstraZeneca/Daiichi Sankyo’s Enhertu has been re...

NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...

Read more
Articles
11.01.2023
What are the 5 Pricing & Market Access trends ...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
News
04.01.2023
PMA Insights: Week 1

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
News
15.12.2022
PMA Insights: Week 50

We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...

Read more
Articles
14.12.2022
2022 Review: Effective P & R Processes to Ens...

We discuss gene therapy pricing and reimbursement, manufacturing methods, analytical analysis, and k...

Read more
30.11.2022
Reflecting on the Pricing & Market Access tren...

Our experts reflect on the trends that shaped the European pricing and market access landscape in 20...

Read more
News
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.